However, the potential sensitivity of certain tumor subsets (e.g., MSI-H or PD-L1-high subgroups) to immunotherapy (14, 39) may counteract the adverse effects of advanced staging on R0 resection. The gene discussed is CD274; the disease is neoplasm.